COMMUNIQUÉS West-GlobeNewswire

Cara Therapeutics to Present at the 27th European Academy of Dermatology & Venereology Congress
05/09/2018
STAMFORD, Conn., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and [...]
ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares
05/09/2018
LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 05, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical company dedicated to changing lives through the creation of transformative RNA [...]
Cytokinetics to Present at the Morgan Stanley Global Healthcare Conference
05/09/2018
SOUTH SAN FRANCISCO, Calif., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at [...]
Get Ready for Flu Season With Oscillococcinum
05/09/2018
NEWTOWN SQUARE, Pa., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Last flu season was the worst in nearly a decade. Health experts are hoping that the intensity of last season will be a wake-up call to how serious flu can be, and [...]
Eckert & Ziegler BEBIG and Eckert & Ziegler Strahlen- und Medizintechnik AG are currently assessing the possibility of a merger between the two companies
05/09/2018
Press release Inside and regulated information 5 September 2018, 19:15 (CEST) Seneffe, Belgium, September 05, 2018. The board of directors of Eckert & Ziegler BEBIG SA ( BEBIG ) and the board of directors of Eckert [...]
Eckert & Ziegler BEBIG et Eckert & Ziegler Strahlen- und Medizintechnik AG évaluent actuellement la possibilité d'une fusion entre les deux sociétés
05/09/2018
Communiqué de presse Information privilégiée et réglementée 5 Septembre, 19h15 (CEST) Seneffe, Belgique, le 5 septembre 2018 . Le conseil d'administration de Eckert & Ziegler BEBIG SA ( BEBIG ) et le conseil d' [...]
Essilor: Disclosure of Share Capital and Voting Rights Outstanding as of August 31, 2018
05/09/2018
Disclosure of Share Capital and Voting Rights Outstanding as of August 31, 2018 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des [...]
Essilor : Nombre total de droits de vote et d'actions composant le capital social au 31 août 2018
05/09/2018
Nombre total de droits de vote et d'actions composant le capital social au 31 août 2018 (Article L.233-8 II du Code de Commerce et les articles 221-1 et 223-16 du Règlement Général de l'AMF) Charenton-le-Pont, France ( [...]
Ramsay Générale de Santé publishes offer document and updates the timetable in its public offer to the shareholders of Capio
05/09/2018
COMMUNIQUÉ DE PRESSE THIS PRESS RELEASE MAY NOT, DIRECTLY OR INDIRECTLY, BE DISTRIBUTED OR PUBLISHED IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, OR SOUTH AFRIC A. THE OFFER IS NOT BEING MADE TO (AND [...]
RAMSAY GENERALE DE SANTE publie un document d'offre et met à jour le calendrier de l'offre publique faite aux actionnaires de Capio
05/09/2018
COMMUNIQUÉ DE PRESSE LE PRESENT COMMUNIQUE DE PRESSE NE PEUT ETRE, DIRECTEMENT OU INDIRECTEMENT, DISTRIBUE OU PUBLIE EN AUSTRALIE, CANADA, HONG KONG, JAPON, NOUVELLE ZELANDE, OU AFRIQUE DU SUD. L'OFFRE N'EST PAS FAITE [...]
BrainStorm Cell Therapeutics Announces New Presentation Time at the H.C. Wainwright & Co. 20th Annual Investor Conference
05/09/2018
Presentation and Live Webcast on Thursday, September 6th, 2.10pm ET NEW YORK and PETACH TIKVAH, Israel, Sept. 05, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult [...]
CV of Inga Krūkle, newly elected Board member of JSC Olainfarm
05/09/2018
CURRICULUM VITAE Inga Krūkle 2011 – 2019 1997 – 2003 EDUCATION: Riga Business school – Professional MBA studies Banking institution of higher education Latvia Professional Bachelor degree in economics 2017 - 2018 2016 [...]
US Department of Defense Reports Travelan Protects Against Shigella in Primates
05/09/2018
Key Highlights: Travelan® pre-clinical shigellosis challenge studies in non-human primates (NHP) successfully completed Travelan® prevented clinical shigellosis (bacillary dysentery) in 75% of Travelan® treated NHPs [...]
Bhang Corporation and Trulieve Announce Licensing Deal to Bring Award-Winning Edible Medical Cannabis Products to Florida
05/09/2018
Bhang products will soon be available to Florida’s more than 150,000 medical cannabis patients, pending regulatory approval by the Office of Medical Marijuana Use MIAMI, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Florida’s [...]
Biothera Pharmaceuticals Announces Immuno-Oncology Clinical Trial Collaboration with AstraZeneca
05/09/2018
Collaboration will evaluate the combination of Biothera’s Imprime PGG and AstraZeneca’s durvalumab in a Phase 2 neoadjuvant study for patients with head and neck cancer EAGAN, Minn., Sept. 05, 2018 (GLOBE NEWSWIRE) -- [...]
Poseida Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Stem Cell Memory Product in Patients with Relapsed/Refractory Multiple Myeloma
05/09/2018
Efficacy and safety continue to be a major advantage, with a very high response rate, no dose limiting toxicities and only a single incidence of suspected cytokine release syndrome P-BCMA-101 clinical data as well as [...]
HIFU Prostate Services Treats 1,000th Patient with HIFU, a Non-Invasive Prostate Cancer Treatment
05/09/2018
HIFU, or high intensity focused ultrasound, is a non-invasive, outpatient, radiation-free treatment for prostate cancer CHARLOTTE, N.C., Sept. 05, 2018 (GLOBE NEWSWIRE) -- HIFU Prostate Services, LLC , the leading [...]
In-Depth Interview: Canadian Farming Royalty Enters The Cannabis Space While Leveraging A Wealth Of Agricultural Experience -- CFN Media
05/09/2018
SEATTLE, Sept. 05, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of [...]
Innovation Pharmaceuticals to Present Brilacidin for Inflammatory Bowel Disease at Inaugural “IBD Innovate 2018” Conference Hosted by the Crohn’s & Colitis Foundation
05/09/2018
BEVERLY, Mass., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today that the Company has been invited to present on the [...]

Pages